Sertindole-Paliperidone

From Psychiatrienet
Jump to: navigation, search
Sertindole
Type Antipsychotic
Group Atypical AP
links
PubChem 60149
PubMed Sertindole
Kompas (Dutch) Sertindole
Wikipedia Sertindole
Paliperidone
Type Antipsychotic
Group Atypical AP
links
Medscape Paliperidone
EMEA invega
PubChem 115237
PubMed Paliperidone
Kompas (Dutch) Paliperidone
Wikipedia Paliperidone

Switch medication from Sertindole to Paliperidone.[1] [2]

Nietinrijdenbord.png Stop Sertindole
  • Day 1-4: approx. 75% of initial dose
  • Day 5-8: approx. 50% of initial dose
  • Day 9-12: approx. 25% of initial dose
  • Day 13: stop
Eenrichtingbord.png Start Paliperidone
  • Day 1-4: approx. 25% of target dose
  • Day 5-8: approx. 50% of target dose
  • Day 9-12: approx. 75% of target dose
  • Day 13: target dose
Letopbord.png Cave
  • During this switch ECG monitoring is required because of possible QT-interval prolongation[3][4]
Infobord.png More information
Switchstandaardup en down.jpg
Nietinrijdenbord.png — Sertindole
Eenrichtingbord.png — Paliperidone


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. SPC Sertindole (Dutch)
  4. SPC Sertindole
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.